Association between myosteatosis and impaired glucose metabolism: A deep learning whole‐body magnetic resonance imaging population phenotyping approach
Journal of Cachexia, Sarcopenia and Muscle · 2024
DOI: 10.1002/jcsm.13527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Matthias Jung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Ger…. Hauptthemen laut MEDLINE: Deep Learning, Magnetic Resonance Imaging. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Helmholtz Association, Leibniz-Gemeinschaft.
Abstract (Originalsprache)
Background
There is increasing evidence that myosteatosis, which is currently not assessed in clinical routine, plays an important role in risk estimation in individuals with impaired glucose metabolism, as it is associated with the progression of insulin resistance. With advances in artificial intelligence, automated and accurate algorithms have become feasible to fill this gap.
Methods
In this retrospective study, we developed and tested a fully automated deep learning model using data from two prospective cohort studies (German National Cohort [NAKO] and Cooperative Health Research in the Region of Augsburg [KORA]) to quantify myosteatosis on whole‐body T1‐weighted Dixon magnetic resonance imaging as (1) intramuscular adipose tissue (IMAT; the current standard) and (2) quantitative skeletal muscle (SM) fat fraction (SMFF). Subsequently, we investigated the two measures for their discrimination of and association with impaired glucose metabolism beyond baseline demographics (age, sex and body mass index [BMI]) and cardiometabolic risk factors (lipid panel, systolic blood pressure, smoking status and alcohol consumption) in asymptomatic individuals from the KORA study. Impaired glucose metabolism was defined as impaired fasting glucose or impaired glucose tolerance (140–200 mg/dL) or prevalent diabetes mellitus.
Results
Model performance was high, with Dice coefficients of ≥0.81 for IMAT and ≥0.91 for SM in the internal (NAKO) and external (KORA) testing sets. In the target population (380 KORA participants: mean age of 53.6 ± 9.2 years, BMI of 28.2 ± 4.9 kg/m 2 , 57.4% male), individuals with impaired glucose metabolism ( n = 146; 38.4%) were older and more likely men and showed a higher cardiometabolic risk profile, higher IMAT (4.5 ± 2.2% vs. 3.9 ± 1.7%) and higher SMFF (22.0 ± 4.7% vs. 18.9 ± 3.9%) compared to normoglycaemic controls (all P ≤ 0.005). SMFF showed better discrimination for impaired glucose metabolism than IMAT (area under the receiver operating characteristic curve [AUC] 0.693 vs. 0.582, 95% confidence interval [CI] [0.06–0.16]; P < 0.001) but was not significantly different from BMI (AUC 0.733 vs. 0.693, 95% CI [−0.09 to 0.01]; P = 0.15). In univariable logistic regression, IMAT (odds ratio [OR] = 1.18, 95% CI [1.06–1.32]; P = 0.004) and SMFF (OR = 1.19, 95% CI [1.13–1.26]; P < 0.001) were associated with a higher risk of impaired glucose metabolism. This signal remained robust after multivariable adjustment for baseline demographics and cardiometabolic risk factors for SMFF (OR = 1.10, 95% CI [1.01–1.19]; P = 0.028) but not for IMAT (OR = 1.14, 95% CI [0.97–1.33]; P = 0.11).
Conclusions
Quantitative SMFF, but not IMAT, is an independent predictor of impaired glucose metabolism, and discrimination is not significantly different from BMI, making it a promising alternative for the currently established approach. Automated methods such as the proposed model may provide a feasible option for opportunistic screening of myosteatosis and, thus, a low‐cost personalized risk assessment solution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Division of Medical Physics, Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Department of Stereotactic and Functional Neurosurgery, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
- Department of Epidemiology, Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany.
- German Center for Diabetes Research (DZD), Neuherberg, Germany.
ORCID-Profile: Matthias Jung
Förderung
- Bundesministerium für Bildung und Forschung
- Helmholtz Association
- Leibniz-Gemeinschaft
Zitieren
APA
Jung, M., Rieder, H., Reisert, M., Rospleszcz, S., Nattenmueller, J., Peters, A., Schlett, C. L., Bamberg, F., & Weiss, J. (2024). Association between myosteatosis and impaired glucose metabolism: A deep learning whole‐body magnetic resonance imaging population phenotyping approach. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13527
Vancouver
Jung M, Rieder H, Reisert M, Rospleszcz S, Nattenmueller J, Peters A, et al. Association between myosteatosis and impaired glucose metabolism: A deep learning whole‐body magnetic resonance imaging population phenotyping approach. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13527
BibTeX
@article{Jung2024,
author = {Jung, Matthias and Rieder, Hanna and Reisert, Marco and Rospleszcz, Susanne and Nattenmueller, Johanna and Peters, Annette and Schlett, Christopher L and Bamberg, Fabian and Weiss, Jakob},
title = {Association between myosteatosis and impaired glucose metabolism: A deep learning whole‐body magnetic resonance imaging population phenotyping approach},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
doi = {10.1002/jcsm.13527}
}
EUVIMED